Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2006-09-05
2006-09-05
Siew, Jeffrey (Department: 1642)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C424S185100, C424S178100, C424S130100, C514S834000, C530S829000
Reexamination Certificate
active
07101557
ABSTRACT:
The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulant-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVIIa activators.
REFERENCES:
patent: 4536387 (1985-08-01), Sakamoto et al.
patent: 5017556 (1991-05-01), O'Brien et al.
patent: 5110730 (1992-05-01), Edgington et al.
patent: 5147638 (1992-09-01), Esmon et al.
patent: 5223427 (1993-06-01), Edgington et al.
patent: 5314695 (1994-05-01), Brown
patent: 5346991 (1994-09-01), Roy et al.
patent: 5374617 (1994-12-01), Morrissey et al.
patent: 5437864 (1995-08-01), Edgington et al.
patent: 5504064 (1996-04-01), Morrissey et al.
patent: 5504067 (1996-04-01), Morrissey et al.
patent: 5589173 (1996-12-01), O'Brien et al.
patent: 5589363 (1996-12-01), Roy et al.
patent: 5622931 (1997-04-01), Edgington et al.
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5726147 (1998-03-01), Ruf et al.
patent: 5739101 (1998-04-01), Roy et al.
patent: 5741658 (1998-04-01), Morrissey
patent: 5750358 (1998-05-01), Morrissey
patent: 5830448 (1998-11-01), Vehar
patent: 5922688 (1999-07-01), Hung et al.
patent: 6001978 (1999-12-01), Edgington et al.
patent: 6132729 (2000-10-01), Thorpe et al.
patent: 6132730 (2000-10-01), Thorpe et al.
patent: 6156321 (2000-12-01), Thorpe et al.
patent: 6303596 (2001-10-01), Morrissey et al.
patent: 0 260 148 (1988-03-01), None
patent: 0 266 993 (1988-05-01), None
patent: 0 278 776 (1988-08-01), None
patent: 458878 (1996-09-01), None
patent: 0 666 868 (2002-04-01), None
patent: WO 88/07543 (1988-10-01), None
patent: WO 93/09804 (1993-05-01), None
patent: WO 93/17715 (1993-09-01), None
patent: WO 93/23074 (1993-11-01), None
patent: WO 94/05328 (1994-03-01), None
patent: WO 94/07515 (1994-04-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 94/28017 (1994-12-01), None
patent: WO 96/01653 (1996-01-01), None
patent: WO 01/54723 (2001-08-01), None
Greenberg et al. New England Journal of Medicine 1994, 331:141-147.
Bach, American Heart Association. 7thNational Conference on Thrombosis and Hemostasis, Nov. 17-20, 1986.
Broze et al., “Purification of Human Brain Tissue Factor,”J. Biol. Chem., 260:10917-10920, 1985.
Carson et al., “Monoclonal Antibodies Against Bovine Tissue Factor, Which Block Interaction With Factor VII,”Blood, 66(1):152-156, 1985.
Giercksky, “The Procoagulant Activity of Adipose Tissue,”Scand J., Haematol., 19:385-395, 1977.
Guha et al., “Affinity Purification of Human Tissue Factor: Interaction of Factor VII and Tissue Factor in Detergent Micelles,”Proc. Natl. Acad. Sci. USA, 83:299-302, 1986.
Morrissey et al., “Resolution of Monomeric and Heterodimeric Forms of Tissue Factor, the High-Affinity Cellular Receptor for Factor VII,”Throm. Res., 50:481-493, 1988.
Morrissey et al., American Heart Association. 7thNational Conference on Thrombosis and Hemostasis, Nov. 17-20, 1986.
Neuenschwander and Morrissey, “Deletion of the Membrane Anchoring Region of Tissue Factor Abolishes Autoactivation of Factor VII but Not Cofactor Function,”J. Biol. Chem., 267:14477, 1992.
Scarpati et al., “Human Tissue Factor: cDNA Sequence and Chromosome Localization of the Gene,”Biochemistry, 26:5234-5238, 1987.
Spicer et al., “Isolation of cDNA Clones Coding for Human Tissue Factor: Primary Structure of the Protein and cDNA,”Proc. Nat., Acad. Sci. USA, 84:5148-5152, 1987.
Van der Besselaar and Bertina, “Interaction of Thromboplastin Apoprotein of Different Tissues with Cohcanavalin A—Evidence for Heterogeneous Glycosylation of the Human Apoprotein,”Throm. Haemostas, 52:192-195, 1984.
Waxman et al., “Tissue Factor and Its Extracellular Soluble Domain: The Relationship Between Intermolecular Association with Factor VIIa and Enzymatic Activity of the Complex,”Biochemistry, 31:3998-4003, 1992.
Wildgoose et al., “Measurement of Basal Levels of Factor VIIa in Hemophilia A and B Patients,”Blood, 80:25, 1992.
Elias et al., “Phase I Study of High-Dose Ifosfamide, Carboplatin and Etoposide with Autologous Hematopoietic Stem Cell Support,”Bone Marrow Transplantation, 15:373-379, 1995.
Greenberg et al., “A Clinical Trial of Antioxidant Vitamins to Prevent Colorectal Adenoma,”N. Engl. J. Med., 331:141-147, 1994.
Martin and Green, “Apoptosis as a Goal of Cancer Therapy,”Oncology, 6:616-621, 1994.
Villikka and Pyrhonen, “Cytokine Therapy of Malignant Melanoma,”Annals of Medicine, 28:227-233, 1996.
Zhang et al., “Tissue Factor Controls the Balance of Angiogenic and Antiangiogenic Properties of Tumor Cells in Mice,”J. Clin. Invest., 94:1320-1327, 1994.
Hardman et al., In Goodman & Gilman's The Pharmacological Basis of Therapeutics Ninth Edition, pp. 51 and 57-58, 1996.
Thorpe, “Vascular Targeting Agents as Cancer Therapeutics,”Clin. Can. Res., 10:415-427, 2004.
Bodey et al., “Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy,”Anticancer Research, 20:2665-2676, 2000.
Ezzell et al., “Cancer “Vaccines”: An Idea Whose Time Has come?,”J. NIH Research, 7:46-49, 1995.
Kuby et al., “Antigens,”Immunology, Second Edition, 85-96, 1944.
Skolnick and Fetrow, “From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era,”TIBTECH, 18:34-39, 2000.
Spitler, “Cancer Vaccines: The Interferon Analog,”Cancer Biotherapy, 10(1):1-3, 1995.
Auerbach, “Vascular Endothelial Cell Differentiation: Organ-Specificity and Selective Affinities as the Basis for Developing Anti-Cancer Strategies,”Int. J. Radiat. Biol., 60(1/2):1-10, 1991.
Brown et al., “Leaky Vessels, Fibrin Deposition, and Fibrosis: A Sequence of Events Common to Solid Tumors and to Many Types of Disease,”Am. Rev. Respir. Dis., 140:1104-1107, 1989.
Clauss et al., “Vascular Permeability Factor: A Tumor-Derived Polypeptide that Induces Endothelial Cell and Monocyte Procoagulant Activity, and Promotes Monocyte Migration,”J. Exp. Med., 172:1535-1545, 1990.
Denekamp, “Vasculature as a Target for Tumour Therapy,”Prog. Appl. Microcirc., 4:28-38, 1984.
Dvorak et al., “Vascular Permeability Factor, Fibrin, and the Pathogenesis of Tumor Stroma Formation,”Ann. N.Y. Acad. Sci., 667:101-111, 1992.
Dvorak, “Leaky Tumor Vessels: Consequences for Tumor Stroma Generation and for Solid Tumor Therapy,”Progress in Clinical and Bioilogical Research, 354a, 317-330, 1990.
Dvorak, “Tumors: Wounds That Do Not Heal,”New Eng. J. Med., 315(26):1650-1659, 1986.
Dvorak et al., “Regulation of Extravascular Coagulation by Microvascular Permeability,”Science, 227:1059-1061, 1985.
Dvorak et al., “Fibrin as a Component of the Tumor Stroma: Origins and Biological Significance,”Cancer Metastasis Reviews, 2:41-73, 1983.
Folkman and Ingber, “Inhibition of Angiogenesis,”Seminars in Cancer Biology, 3:89-96, 1992.
Folkman and Shing, “Angiogenesis,”J. Biol. Chem., 267(16):10931-10934, 1992.
Folkman et al., “Induction of Angiogenesis During the Transition from Hyperplasia to Neoplasia,”Nature, 339:58-61, 1989.
Folkman, “What is the Evidence that Tumors are Angiogenesis Dependent?,”J. Natl. Cancer Inst., 82(1):4-6, 1990.
Folkman and Klagsbrun, “Angiogenic Factors,”Science, 23
Gao Boning
King Steven W.
Thorpe Philip E.
Aeder Sean E
Board of Regents , The University of Texas System
Fussey Shelley P. M.
Siew Jeffrey
LandOfFree
Combined tissue factor methods for coagulation and tumor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combined tissue factor methods for coagulation and tumor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined tissue factor methods for coagulation and tumor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3555936